Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target
Noble Capital Markets initiated company-sponsored research coverage of Cosmos Health with an Outperform rating and a $1.40 price target, roughly 493% above the October 27 close of $0.236. The report forecasts revenue growing from $90.0 million in 2026 to $131.2 million in 2027 and $160.8 million in 2028, with adjusted EBITDA turning positive at $3.9 million in 2026 and reaching $27.4 million by 2028.
Key figures
- Upside pct
- approximately 493%
- Prior close
- 0.236
- Price target
- 1.4
- Noble 2027 fcf estimate
- 10000000
- Noble 2028 fcf estimate
- 16800000
- Noble 2026 revenue estimate
- 90000000
- Noble 2027 revenue estimate
- 131200000
- Noble 2028 revenue estimate
- 160800000
- Noble 2026 adj ebitda estimate
- 3900000
- Noble 2027 adj ebitda estimate
- 16700000
- Noble 2028 adj ebitda estimate
- 27400000
- Noble q4 2026 revenue estimate
- 35700000
- Noble q4 2026 adj ebitda estimate
- 6400000
- Noble q4 2026 gross margin estimate
- 40.1%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.